These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36. Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial. Kuter DJ; Bonkovsky HL; Monroy S; Ross G; Guillén-Navarro E; Cappellini MD; Minder AE; Hother-Nielsen O; Ventura P; Jia G; Sweetser MT; Thapar M; J Hepatol; 2023 Nov; 79(5):1150-1158. PubMed ID: 37479139 [TBL] [Abstract][Full Text] [Related]
37. Pain in acute hepatic porphyrias: Updates on pathophysiology and management. Kazamel M; Pischik E; Desnick RJ Front Neurol; 2022; 13():1004125. PubMed ID: 36479055 [TBL] [Abstract][Full Text] [Related]
38. Best practice guidelines on first-line laboratory testing for porphyria. Woolf J; Marsden JT; Degg T; Whatley S; Reed P; Brazil N; Stewart MF; Badminton M Ann Clin Biochem; 2017 Mar; 54(2):188-198. PubMed ID: 27555665 [TBL] [Abstract][Full Text] [Related]
39. Brazilian registry of patients with porphyria: REBRAPPO study. Souza PVS; Afonso G; de Rezende Pinto WBV; de Lima Serrano P; de Mattos Lombardi Badia B; Farias IB; Dos Santos Jorge AC; Machado RIL; Pinto IFN; Barros GB; de Oliveira HB; Calil SR; Franz C; Oliveira ASB Orphanet J Rare Dis; 2023 Mar; 18(1):49. PubMed ID: 36890577 [TBL] [Abstract][Full Text] [Related]
40. Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels. Agarwal S; Habtemarium B; Xu Y; Simon AR; Kim JB; Robbie GJ JIMD Rep; 2021 Jan; 57(1):85-93. PubMed ID: 33473344 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]